Year : 2020  |  Volume : 32  |  Issue : 3  |  Page : 128-131

Optimizing anticancer therapy in newly diagnosed metastatic castration sensitive prostate cancer

Department of Urology, Ygeias Melathron Hospital, TYPET, Athens, Greece

Correspondence Address:
Anastasios Thanos
Department of Urology, Ygeias Melathron Hospital-TYPET, Therianou 4-6, Athens, PC:11473
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/HUAJ.HUAJ_19_20

Rights and Permissions

Historically, androgen deprivation therapy has been the standard of care in the management of metastatic castration sensitive prostate cancer (mCSPC). However, during the past 5 years, numerous different treatment options have become available and have been set under investigation. The addition of docetaxel or abiraterone acetate has improved outcomes for patients with mCSPC and has become a new standard of care. New drugs targeting androgen receptor axis, local therapy including surgery, radiotherapy, and brachytherapy as well as metastatic-directed treatments have also demonstrated promising outcomes. In this work, the available data on all treatment modalities employed in mCSPC are being reviewed.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded124    
    Comments [Add]    

Recommend this journal